North Carolina Senate Race Could Feature Bid By Rep. Burr
Executive Summary
One of the brand name pharmaceutical industry's strongest allies in the House, Rep. Burr (R-N.C.), is considering running for the North Carolina Senate seat to be vacated by the retirement of Sen. Helms' (R-N.C.) in 2002.
You may also be interested in...
Celebrex Growth Is "Typical" Of NSAIDs After Three Years, Pharmacia Says
Pharmacia's Celebrex is showing a growth curve that is typical for products in the non-steroidal anti-inflammatory class, CEO Fred Hassan acknowledged during a July 25 analysts call.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials